Beta: Sign in
Shares outstandingAs of 2026-08-13 · filed common shares: 3.56M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 2.76%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 2.43%
Short ratioDays to cover, as published by FINRA: 1.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 61.00%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 54.20%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -275.16%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -199.59%

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Mar 26

-5.59

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $2.38M
Total cash: Sign in
Total debt: —
Debt / equity: —
Current ratioas of Jun 26: 3.73
Quick ratio: —
Operating cash flowTTM to Jun 26: -$10.16M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$10.16M
TTM revenue / diluted share: —

CVKD stock Statistics — Cadrenal Therapeutics, Inc. filings, insiders & smart money · Instaport